A comparison of different management techniques for myocardial protection in acyanotic congenital cardiac patients

Aim: It has already been shown that terminal warm blood cardioplegia (TWBC) supports myocardial protection in pediatric patients when it is administered after cold blood cardioplegia. However, the myocardial protective effects of TWBC applied after cold crystalloid cardioplegia (CCC) is still a subject of debate. Materials and methods: Twenty acyanotic congenital cardiac patients were randomly divided into 2 groups of 10. In the control group (CG), moderate hypothermia, topical cooling, and cold crystalloid cardioplegia were performed for the protection of the myocardium. In the other group (TWBCG), the same procedure was supported using TWBC just before the unclamping of the aorta. Blood samples were analyzed to discover the progression of anaerobic energy metabolism potentially causing injury of the myocardium during the ischemic, reperfusion, and postoperative period. Results: There were no significant statistical differences in age, body weight, mean pulmonary artery pressure, operation procedure, cardiopulmonary bypass and aortic cross clamping time, period of respiratory support, and intensive care unit and hospital stay. Also measurement of serum cardiac troponin T (TnT), creatine kinase MB(CK-MB), and lactate levels preoperatively, just after the release of the cross clamp and at the time of postoperative 4, 12, 24, and 48 h showed no significant differences either. Conclusion: TWBC was not able to enhance the myocardial protective effects in acyanotic congenital cardiac patients when performed in addition to CCC.

Anahtar Kelimeler:

Key words: Myocardial protection, terminal warm blood cardioplegia, cold crystalloid cardioplegia

A comparison of different management techniques for myocardial protection in acyanotic congenital cardiac patients

Keywords:

Key words: Myocardial protection, terminal warm blood cardioplegia, cold crystalloid cardioplegia,

PDF

___

1. Allen BS. Pediatric myocardial protection: where do we stand? J Thorac Cardiovasc Surg 2004; 128(1): 11-3.
2. Bretschneider HJ. Myocardial protection. Thorac Cardiovasc Surg 1980; 28(5): 295-302.
3. Bigelow WG, Lindsay WK, Greenwood WF. Hypothermia; its possible role in cardiac surgery: an investigation of factors governing survival in dogs at low body temperatures. Ann Surg 1950; 132(5): 849-66.
4. Teoh KH, Christakis GT, Weisel RD, Fremes SE, Mickle DA, Romaschin AD, Harding RS et al. Accelerated myocardial metabolic recovery with terminal warm blood cardioplegia. J Thorac Cardiovasc Surg 1986; 91(6): 888-95.
5. Caputo M, Dihmis WC, Bryan AJ, Suleiman MS, Angelini GD. Warm blood hyperkalaemic reperfusion ('hot shot') prevents myocardial substrate derangement in patients undergoing coronary artery bypass surgery. Eur J Cardiothorac Surg. 1998; 13(5): 559-64.
6. Nomura F, Forbess JM, Mayer EJ. Effects of Hot shot on recovery after hypothermic ischemia in neonatal lamb heart. J Cardiovasc Surg (Torino). 2001; 42(1): 1-7.
7. Kronon MT, Allen BS, Rahman S, Wang T, Tayyab NA, Bolling KS, Ilbawi MN. Reducing postischemic reperfusion damage in neonates using a terminal warm substrate-enriched blood cardioplegic reperfusate. Ann Thorac Surg. 2000; 70(3): 765-70.
8. Kawasuji M, Tomita S, Yasuda T, Sakakibara N, Takemura H, Watanabe Y. Myocardial oxygenation during terminal warm blood cardioplegia. Ann Thorac Surg 1998; 65(5): 1260-4.
9. Modi P, Suleiman MS, Reeves B, Pawade A, Parry AJ, Angelini GD, Caputo M. Myocardial metabolic changes during pediatric cardiac surgery: a randomized study of 3 cardioplegic techniques. J Thorac Cardiovasc Surg 2004; 128(1): 67-75.
10. Toyoda Y, Yamaguchi M, Yoshimura N, Oka S, Okita Y. Cardioprotective effects and the mechanisms of terminal warm blood cardioplegia in pediatric cardiac surgery. J Thorac Cardiovasc Surg 2003; 125(6): 1242-51.
11. Caputo M, Modi P, Imura H, Pawade A, Parry AJ, Suleiman MS, Angelini GD. Cold blood versus cold crystalloid cardioplegia for repair of ventricular septal defects in pediatric heart surgery: a randomized controlled trial. Ann Thorac Surg. 2002; 74(2): 530-4; discussion 535.
12. Hammon JW Jr. Myocardial protection in the immature heart. Ann Thorac Surg 1995; 60(3): 839-42.
13. Hearse DJ. Reperfusion of the ischemic myocardium. J Mol Cell Cardiol 1977; 9(8): 605-16.
14. Follette DM, Fey K, Buckberg GD, Helly JJ Jr, Steed DL, Foglia RP, Maloney JV, Jr. Reducing postischemic damage by temporary modification of reperfusate calcium, potassium, pH, and osmolarity. J Thorac Cardiovasc Surg 1981; 82(2): 221-38.
15. Kirklin J, Barrat-Boyes B. Myocardial management during cardiac surgery with cardiopulmonary bypass. In: Kirklin J, Barrat-Boyes B, eds. Cardiac surgery. 2nd ed. New York: Churchill Livingstone, 1993: 129-66.
16. Taggart DP, Hadjinikolas L, Hooper J, Albert J, Kemp M, Hue D, Yacoub M, Lincoln JC. Effects of age and ischemic times on biochemical evidence of myocardial injury after pediatric cardiac operations. J Thorac Cardiovasc Surg 1997; 113(4): 728- 35.
17. Buckberg GD, Allen BS. Myocardial protection management during adult cardiac operations. In: Baue AE, Geha AS, Hammond GL, Laks H, Naunheim KS, editors. Glenn’s thoracic and cardiovascular surgery. 6th ed. New York: Appleton and Lange; 1995. p. 1653-87.